Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GLAXO U.S. SALES TOP $ 1 BIL. IN FY 1988 TO COMPRISE ALMOST 40% OF CORPORATE VOLUME; ZANTAC LIFTS GLAXO TO WORLD's SECOND LARGEST Rx FIRM BEHIND MERCK

Executive Summary

Glaxo's annual U.S. sales volume increased 37% during the 12 months ended June 30 and surpassed $ 1 bil. for the first time in company history. "Growth in the U.S. continues to be outstanding, as sales increased 37% in dollars to $ 1.3 bil, compared with $ 937 mil. in fiscal 1987," the British firm noted in a Sept. 19 press release. "Glaxo's U.S. subsidiary, Glaxo Inc., is ranked in the top ten of the U.S. pharmaceutical industry and contributed about 36% of total group sales in sterling terms." Glaxo said that while its anti-ulcer product Zantac "continues on its extraordinary path of growth," the company sustained higher rates of sales growth in the respiratory and antibiotic areas, "in some cases with products which were introduced into the market many years before Zantac." Sales increases were achieved in all therapeutic categories, Glaxo added. Overall corporate volume was up 26% in terms of U.S. dollars, to $ 3.5 bil. while net earnings approached the $ 1 bil. mark, rising 22% to $ 976 mil. However, in terms of British pounds, worldwide sales and net income reflected 12-month gains of 18% to (BRITISH POUND)2.1 bil. and 15% to (BRITISH POUND)571 mil, respectively, the result of a declining dollar against the British pound in fiscal 1988. The firm also noted that during fiscal 1988, Glaxo became "the world's second largest pharmaceutical company," behind Merck. A higher level of R&D activity resulted in a 50% increase in R&D expenditures to (BRITISH POUND)230 mil. ( $ 393 mil.). However, Glaxo said that the increase was "an exceptional rise" and that R&D spending was not expected to continue at that rate. Chart omitted.
UsernamePublicRestriction

Register

PS014327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel